- Home
- AIDX vs XRTX Comparison
AIDX vs XRTX Comparison
Compare AIDX & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIDX | XRTX |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 3.9M |
| IPO Year | 2025 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AIDX | XRTX |
|---|---|---|
| Price | $0.37 | $1.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 54.7K | ★ 410.9K |
| Earning Date | 11-15-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.48 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,045,133.00 | N/A |
| Revenue This Year | $44.20 | N/A |
| Revenue Next Year | $95.73 | $392.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.71 | N/A |
| 52 Week Low | $0.33 | $0.35 |
| 52 Week High | $14.09 | $3.60 |
Technical Indicators
Market Signals| Indicator | AIDX | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.59 | 33.84 |
| Support Level | N/A | $0.37 |
| Resistance Level | $0.49 | $2.29 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 25.03 | 2.74 |
Price Performance
Historical ComparisonAbout AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.